Redhill Biopharma Ltd (NAS:RDHL)
RedHill Biopharma Ltd. is a NASDAQ listed drug manufacturer based in Israel. The company is focused on late clinical-stage, orally-administered drugs for the treatment of internal inflammatory disorders such as gastroenteritis.
|10 Days Avg Vol||110,392.70|
|3 Mo Avg Vol||119,191.76|
|52 Wk Lo/Hi||$4.300 - $11.250|
|YTD Price Gain %||108.19%|
|12 Wks Moving Avg||6.590678|
|200 Days Moving Avg||6.342110|
Updated: Market Close, 07/13/2018
RedHill Biopharma Ltd. is an Israel-based developer of pharmaceutical products addressing multiple diseases. Its primary focus lies on late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of internal inflammatory disorders and cancer. Redhill's assortment of drugs includes RHB-105, which combats the Helicobacter pylori infection; RHB-104, which treats the Crohn's disease and RIZAPORT, for acute migraines. The BEKINDA, YELIVA and MESUPRON were formulated for acute gastroenteritis and other critical inflammatory conditions.
No management profiles found.